- A new study has explored the potential of generating T lymphocytes from hematopoietic stem cells (HSCs) for cancer immunotherapy.
- HSCs are a type of cell that can differentiate into various blood cells, including T lymphocytes, which are a key player in the immune system’s fight against cancer.
- The researchers successfully generated HSC-derived T lymphocytes (HSC-T) with robust expansion.
- The HSC-T cells were found to have preserved T-cell efficacy, including the ability to secrete cytokines and cytotoxic granules.
- The HSC-T cells were also successfully transduced with a chimeric antigen receptor (CAR) and showed higher cytokine secretion and a trend of superior cytotoxicity against target cells compared to control CAR-T cells.
- This approach could offer an alternative option for cellular immunotherapy, especially for patients with limited T-cell function or an inadequate number of T cells for CAR T-cell therapy.
เงินทุน
- คณะแพทยศาสตร์ มหาวิทยาลัยสงขลานครินทร์
- สำนักงานคณะกรรมการวิจัยแห่งชาติ (วช.)
- Royal King Ananda Mahidol Foundation
กระดาษต้นฉบับ
ชื่อบทความต้นฉบับ: Generation of ex vivo autologous hematopoietic stem cell-derived T lymphocytes for cancer immunotherapy
วารสาร: Heliyon
ดอย: https://doi.org/10.1016/j.heliyon.2024.e38447